254 related articles for article (PubMed ID: 17634556)
1. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model.
Mabuchi S; Altomare DA; Cheung M; Zhang L; Poulikakos PI; Hensley HH; Schilder RJ; Ozols RF; Testa JR
Clin Cancer Res; 2007 Jul; 13(14):4261-70. PubMed ID: 17634556
[TBL] [Abstract][Full Text] [Related]
2. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.
Mabuchi S; Altomare DA; Connolly DC; Klein-Szanto A; Litwin S; Hoelzle MK; Hensley HH; Hamilton TC; Testa JR
Cancer Res; 2007 Mar; 67(6):2408-13. PubMed ID: 17363557
[TBL] [Abstract][Full Text] [Related]
3. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines.
Ma BB; Lui VW; Hui EP; Lau CP; Ho K; Ng MH; Cheng SH; Tsao SW; Chan AT
Invest New Drugs; 2010 Aug; 28(4):413-20. PubMed ID: 19471857
[TBL] [Abstract][Full Text] [Related]
4. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.
Mabuchi S; Kawase C; Altomare DA; Morishige K; Sawada K; Hayashi M; Tsujimoto M; Yamoto M; Klein-Szanto AJ; Schilder RJ; Ohmichi M; Testa JR; Kimura T
Clin Cancer Res; 2009 Sep; 15(17):5404-13. PubMed ID: 19690197
[TBL] [Abstract][Full Text] [Related]
5. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
[TBL] [Abstract][Full Text] [Related]
6. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
Treeck O; Wackwitz B; Haus U; Ortmann O
Gynecol Oncol; 2006 Aug; 102(2):292-9. PubMed ID: 16443261
[TBL] [Abstract][Full Text] [Related]
7. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
8. In vivo and in vitro effects of RAD001 on bladder cancer.
Vasconcelos-Nóbrega C; Pinto-Leite R; Arantes-Rodrigues R; Ferreira R; Brochado P; Cardoso ML; Palmeira C; Salvador A; Guedes-Teixeira CI; Colaço A; Palomino LF; Lopes C; Santos L; Oliveira PA
Urol Oncol; 2013 Oct; 31(7):1212-21. PubMed ID: 22169072
[TBL] [Abstract][Full Text] [Related]
9. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
Grozinsky-Glasberg S; Rubinfeld H; Nordenberg Y; Gorshtein A; Praiss M; Kendler E; Feinmesser R; Grossman AB; Shimon I
Mol Cell Endocrinol; 2010 Feb; 315(1-2):87-94. PubMed ID: 19815051
[TBL] [Abstract][Full Text] [Related]
10. Autophagy inhibition enhances RAD001-induced cytotoxicity in human bladder cancer cells.
Lin JF; Lin YC; Yang SC; Tsai TF; Chen HE; Chou KY; Hwang TI
Drug Des Devel Ther; 2016; 10():1501-13. PubMed ID: 27143856
[TBL] [Abstract][Full Text] [Related]
11. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
Loehberg CR; Strissel PL; Dittrich R; Strick R; Dittmer J; Dittmer A; Fabry B; Kalender WA; Koch T; Wachter DL; Groh N; Polier A; Brandt I; Lotz L; Hoffmann I; Koppitz F; Oeser S; Mueller A; Fasching PA; Lux MP; Beckmann MW; Schrauder MG
Biochem Pharmacol; 2012 Feb; 83(4):480-8. PubMed ID: 22142888
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer.
Manegold PC; Paringer C; Kulka U; Krimmel K; Eichhorn ME; Wilkowski R; Jauch KW; Guba M; Bruns CJ
Clin Cancer Res; 2008 Feb; 14(3):892-900. PubMed ID: 18245553
[TBL] [Abstract][Full Text] [Related]
13. Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001.
Kuo SH; Hsu CH; Chen LT; Lu YS; Lin CH; Yeh PY; Jeng HJ; Gao M; Yeh KH; Cheng AL
Eur J Cancer; 2011 May; 47(8):1244-57. PubMed ID: 21334199
[TBL] [Abstract][Full Text] [Related]
14. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth.
Altomare DA; Wang HQ; Skele KL; De Rienzo A; Klein-Szanto AJ; Godwin AK; Testa JR
Oncogene; 2004 Jul; 23(34):5853-7. PubMed ID: 15208673
[TBL] [Abstract][Full Text] [Related]
15. mTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells.
Cai Y; Xia Q; Su Q; Luo R; Sun Y; Shi Y; Jiang W
Int J Mol Med; 2013 Apr; 31(4):904-12. PubMed ID: 23426850
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
Boulay A; Rudloff J; Ye J; Zumstein-Mecker S; O'Reilly T; Evans DB; Chen S; Lane HA
Clin Cancer Res; 2005 Jul; 11(14):5319-28. PubMed ID: 16033851
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
Chan SL; Wong CH; Lau CP; Zhou Q; Hui CW; Lui VW; Ma BB; Chan AT; Yeo W
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1417-25. PubMed ID: 23546591
[TBL] [Abstract][Full Text] [Related]
18. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.
Beuvink I; Boulay A; Fumagalli S; Zilbermann F; Ruetz S; O'Reilly T; Natt F; Hall J; Lane HA; Thomas G
Cell; 2005 Mar; 120(6):747-59. PubMed ID: 15797377
[TBL] [Abstract][Full Text] [Related]
19. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.
Macaskill EJ; Bartlett JM; Sabine VS; Faratian D; Renshaw L; White S; Campbell FM; Young O; Williams L; Thomas JS; Barber MD; Dixon JM
Breast Cancer Res Treat; 2011 Aug; 128(3):725-34. PubMed ID: 20941539
[TBL] [Abstract][Full Text] [Related]
20. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
Aide N; Kinross K; Cullinane C; Roselt P; Waldeck K; Neels O; Dorow D; McArthur G; Hicks RJ
J Nucl Med; 2010 Oct; 51(10):1559-64. PubMed ID: 20847160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]